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Background: HIV-associated cryptococcal meningitis accounts for 
15% of AIDS related deaths globally. In sub-Saharan Africa, acute 
mortality ranges from 24% to 100%. In addition to the mortality 
directly associated with cryptococcosis, patients with HIV-associated 
cryptococcal meningitis are at risk of a range of opportunistic 
infections (OIs) and hospital acquired nosocomial infections (HAIs). 
The attributable mortality associated with co-prevalent infections in 
cryptococcal meningitis has not been evaluated.  
Methods: As part of the Advancing Cryptococcal meningitis Treatment 
for Africa (ACTA) trial, consecutive HIV-positive adults with 
cryptococcal meningitis were randomised to one of five anti-fungal 
regimens and followed up until 10-weeks. We conducted a 
retrospective case note review of ACTA participants recruited from 
Queen Elizabeth Central Hospital in Blantyre, Malawi to describe the 
range and prevalence of OIs and HAIs diagnosed, and the attributable 
mortality associated with these infections.  
Results: We describe the prevalence of OIs and HAIs in 226 
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participants. Baseline median CD4 count was 29 cell/mm3, 57% 
(129/226) were on anti-retroviral therapy. 56% (127/226) had at least 
one co-prevalent infection during the 10-week study period. Data 
were collected for 187 co-prevalent infection episodes. Suspected 
blood stream infection was the commonest co-prevalent infection 
diagnosed (34/187, 18%), followed by community-acquired 
pneumonia (32/187, 17%), hospital-acquired pneumonia (13/187, 7%), 
pulmonary tuberculosis (12/187, 6%) and confirmed blood stream 
infections (10/187, 5%). All-cause mortality at 10-weeks was 35% 
(80/226), diagnosis of an OI or HAI increased the risk of death at 10 
weeks by nearly 50% (HR 1.48, 95% CI 1.01-2.17, p=0.04). 
Conclusion: We demonstrate the high prevalence and broad range of 
OIs and HAIs occurring in patients with HIV-associated cryptococcal 
meningitis. These co-prevalent infections are associated with a 
significantly increased risk of death. Whether a protocolised approach 
to improve surveillance and proactive treatment of co-prevalent 
infections would improve cryptococcal meningitis outcomes warrants 
further investigation.
Keywords 
cryptococcal meningitis, opportunistic infections, hospital acquired 
infections, nosocomial infections, HIV/AIDS, Africa
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Introduction
Cryptococcal meningitis is the commonest neurological com-
plication in patients with advanced HIV disease, accounting 
for 15% of AIDS related deaths globally1. In sub-Saharan 
Africa, mortality ranges from 24%2 to 100%3. Even in the 
context of clinical trials with delivery of rapidly fungicidal 
amphotericin-based regimens, case fatality is 24–45%4. We 
hypothesise therefore that in addition to the mortality directly 
associated with cryptococcal meningitis, patients with HIV-
associated meningitis are also at risk of a range of opportun-
istic infections (OIs) and hospital acquired infections (HAIs) 
resulting from the prolonged hospitalization required for current 
treatment regimens. Co-prevalent human herpesvirus viraemias 
(2–28%)5 and nosocomial bacteraemias (15%)6 in cryptococ-
cal cohorts have previously been reported, and there are reports 
of cryptococcal meningitis coinfection with tuberculosis7–9 
(including TB meningitis10), and pneumocystis pneumonia11. 
However, the overall morbidity and mortality associated 
with OIs and HAIs in patients undergoing treatment for HIV- 
associated cryptococcal meningitis has not been ascertained. 
Understanding this impact may aid design of enhanced infection 
screening and treatment interventions to reduce mortality. 
As part of the Advancing Cryptococcal meningitis Treatment 
for Africa (ACTA) trial4, we described the range and prevalence 
of OIs and HAIs in patients undergoing treatment for cryp-
tococcal meningitis, and the attributable mortality associated 
with these infections.
Methods
The ACTA trial was a multi-centre randomised controlled trial 
which investigated the optimal treatment of HIV-associated 
cryptococcal meningitis in resource limited settings 
(ISRCTN45035509)4. From January 2013 to November 2016, 
721 consecutive HIV-positive adults with cryptococcal meningitis 
were randomised to one of three treatment strategies: oral fluco-
nazole plus flucytosine for two weeks, one-week Amphotericin 
B (AmB)-based therapy, and standard two weeks AmB-based 
therapy. Those in the AmB arms were further randomized to 
flucytosine or fluconazole in a 1:1 ratio, as the partner drug 
given with AmB. Patients received consolidation flucona-
zole therapy after the two-week induction period: 800 mg until 
anti-retroviral therapy (ART) initiation or switch at 4 weeks 
and 400 mg to 10 weeks. ART was prescribed according to 
national guidelines, naïve patients were commenced on ART 
at week 4. The primary endpoint was all-cause mortality at 
two-weeks and follow up was until 10-weeks.
We conducted a retrospective case note review of all ACTA 
participants recruited from Queen Elizabeth Central Hospital 
in Blantyre, Malawi between November 2016 and July 2018. 
This site was the largest contributor to the trial and detailed 
OI and HAI information was only collected at this site. Patient 
demographics, clinical history, laboratory investigations, and 
outcome data were collected as part of the trial. Case notes were 
reviewed and details recorded regarding the nature, timing, 
diagnosis and treatment for incident OIs and HAIs.
Categorisation of opportunistic infections
Diagnoses were ascribed by the study physician based on 
standard clinical case definitions and investigations and treat-
ment were according to the Malawian National Clinical 
Care guidelines. Routinely available investigations included: 
haematology and biochemistry blood tests, chest radiography, 
ultrasonography, sputum microscopy and Xpert MTB/RIF for 
investigation of TB, malaria rapid diagnostic test and blood 
smear, urine microscopy, culture and sensitivity (MC&S), 
blood cultures and cerebrospinal fluid MC&S. Due to resource 
constraints, markers of sepsis were limited to those which 
could be assessed clinically or through simple laboratory tests. 
Suspected blood stream infection (sBSI) was ascribed when 
at least two of the following criteria were met: (i) temperature 
< 35°C or >38.3°C; (ii) respiratory rate >20 breaths/minute; 
(iii) pulse >90 beats/minute; (iv) white cell count >12 or 
<4×109 cells/l, but where no causative organism was identi-
fied at blood culture as per previous modified sepsis criteria used 
in our setting12. Data were collected on all physician diagnosed 
OIs and HAIs during the study period (Table 1). The follow-
ing diagnoses were pre-specified as major co-prevalent infec-
tions associated with high risk of acute inpatient mortality: 
(1) pulmonary tuberculosis (PTB); (2) extra-PTB; (3) confirmed 
blood stream infection (cBSI); (4) sBSI; (5) acute respiratory ill-
ness (ARI), which included community- or hospital-acquired 
pneumonia and aspiration pneumonia.
Statistical analysis
Descriptive data used counts and percentages for categorical 
variables, and medians and interquartile ranges (IQR) for 
continuous variables. Time from randomisation to death due to 
any cause was analysed using survival analysis based on 
the Cox Proportional Hazard (PH) model with time-varying 
covariates. Hazard ratio (HR) of death and its corresponding 95% 
confidence interval (CI) for number of major OIs was estimated. 
To control possible confounding, the Cox model was adjusted 
for the following predictors; sex, age, anti-fungal regimen, 
ART use, baseline haemoglobin and quantitative cryptococcal 
fungal burden. Number of OIs was included in the survival model 
as a time-varying co-variate, to incorporate that fact that these 
illnesses were not all present at baseline but presented at vari-
able times (0–2 weeks and/or 2–10 weeks) during the study 
period. The Cox PH assumption was assessed by testing the 
interaction between each predictor variable and time (log-scale). 
Analysis was conducted using R software version 3.4.4, and 
all tests were performed at 5% significance level.
Ethics
The ACTA trial protocol was approved by the London School 
of Hygiene and Tropical Medicine Research Ethics Committee 
(REC) (8854 – 5) and the University of Malawi, College 
of Medicine Research Ethics Committee (COMREC) 
(P.11/11/1149). Written informed consent was obtained from 
all participants. This analysis was part of the pre-specified aims 
of the ACTA protocol and the trial remained open during the 
data extraction for this study.
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Results
In total, 226 out of 255 (89%) patients with HIV-associated 
cryptococcal meningitis recruited into the ACTA trial were 
included in the analysis; the remaining 29/255 patients were not 
included due to incomplete clinical data. The median age was 
36 years (IQR 32–43 years), and 57% were male. All participants 
had advanced HIV; baseline median CD4 count was 29 cell/mm3 
(IQR 12–64 cell/mm3), baseline haemoglobin was 11.1g/dL (IQR 
9.8–12.3g/dL). At recruitment, 57% (129/226) were on ART. 
All-cause mortality at 10-weeks was 35% (80/226), median time 
to death was 14.5 days (IQR 3–29 days).
Out of the 226 patients, 127 (56%) patients had at least one 
OI or HAI diagnosed during the 10-week study period. A total 
of 39% (89/226) had a single co-prevalent infection diagnosed, 
11% (26/226) had two, 4% (8/226) had three, and 1% had 
either four or more. Data were collected on a total of 187 
co-prevalent infection episodes (Table 1). sBSI was the common-
est co-prevalent infection diagnosed (34/187, 18%), followed 
by community-acquired pneumonia (32/187, 17%), aspiration 
pneumonia (15/187, 8%), hospital-acquired pneumonia (13/187, 
7%), chronic diarrhoea (13/187, 7%), pulmonary TB (12/187, 6%) 
and cBSIs (10/187, 5%).
A range of bacterial pathogens were isolated from blood, 
including four multidrug resistant (MDR) bacteria: extended 
spectrum beta lactamase producing Escherichia coli (n=2), 
MDR Salmonella typhi (n=1), MDR Salmonella typhimurium 
Table 1. Range and prevalence of opportunistic infections diagnosed 
in patients undergoing treatment for HIV-associated cryptococcal 
meningitis. 187 opportunistic infections (OIs) were diagnosed in 226 patients 
during the study period. 39% (89/226) had a single OI diagnosed, 11% 
(26/226) had two OIs, 4% (8/226) had three OIs and 1% had either four or 
more OIs diagnosed. A wide range of infections were diagnosed; suspected 
blood stream infection was the commonest opportunistic infection diagnosed 
(18%), followed by community acquired pneumonia (17%), aspiration 
pneumonia (8%), hospital acquired pneumonia (7%).




Suspected blood stream infection 34 (18)
Confirmed bacteraemia 10 (5)
Respiratory infections/
tuberculosis (TB)
Community acquired pneumonia 32 (17)
Hospital acquired pneumonia 13 (7)
Aspiration pneumonia 15 (8)
Pneumocystis pneumonia 1 (0.5)
Pulmonary TB 12 (6)
Extrapulmonary TB (unspecified) 8 (4)
TB meningitis 5 (3)











1 Sexually transmitted/genitourinary infections included: genital ulcer disease, pelvic 
inflammatory disease, syphilis and urinary tract infections.
2 Skin/soft tissue/mucosal/ophthalmic infections included: Kaposi’s Sarcoma, skin abscess, 
tinea corporis, candidiasis and conjunctivitis.
3 Gastro-intestinal/abdominal infections included: acute gastroenteritis, chronic diarrhoea 
and wasting, hepatic abscesses, splenic abscesses.
4 Other = malaria
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(n=4), Methicillin-resistant Staphylococcus aureus (n=1), 
Streptococcus pneumoniae (n=1), and Klebsiella pneumoniae 
(n=1).
A total of 134 infection episodes met the pre-defined criteria 
for a major co-prevalent infection; 30% (40/134) were diag-
nosed on study day one. The median time to diagnosis of a major 
co-prevalent infection was 9 days (IQR 1–27 days), 53% (71/134) 
of major co-prevalent infections were diagnosed at least two 
weeks after the commencement of anti-fungal therapy. Risk 
of all-cause mortality at 10 weeks was significantly increased 
(p = 0.04) if a participant was diagnosed with any one of the 
pre-specified major co-prevalent infections (HR 1.48, 95% 
CI 1.01-2.17). Results were similar for all pre-specified adjusted 
analyses, other than fungal burden which was an independent 
predictor of mortality. 
Discussion
We show that co-prevalent OIs and HAIs are common in 
adults with HIV-associated cryptococcal meningitis with more 
than half of participants being diagnosed with at least one 
co-prevalent infection during the 10-week study period. We also 
demonstrate that diagnosis of a major co-prevalent infection 
(suspected or confirmed BSI, tuberculosis, or ARI (community- 
or hospital-acquired pneumonia and aspiration pneumonia)) was 
associated with nearly a 50% increased risk of death (HR 1.48, 
p=0.04) amongst our cohort. Whilst one third of these major 
co-prevalent infections were diagnosed at study entry, the 
median time to diagnosis was nine days, either indicating noso-
comial acquisition or delayed diagnosis. It is essential there-
fore that physicians treating patients with HIV-associated 
cryptococcal meningitis remain vigilant for OIs and HAIs, and 
consider the sub-group of patients with co-prevalent infections 
as particularly high-risk of death.
Consistent with other cryptococcal meningitis studies in low 
resource, high HIV prevalence settings, the 10-week all-cause 
mortality was high in our cohort (35%)13,14. Deaths occurred 
throughout the study period with 50% of deaths occurring in the 
first 14 days. It has been postulated from previous HIV-associated 
cryptococcal meningitis trials15, that acute deaths (≤2 weeks) 
are more likely to be attributable to cryptococcal meningitis, 
whilst after two weeks other HIV-related causes of death 
predominate. Although it is likely that cryptococcal meningitis 
was the primary cause of death for the majority of patients in 
our cohort, the time-distribution of deaths also supports our 
hypothesis that other co-prevalent infections contribute to the 
considerable mortality in this severely immunocompromised 
group. Post-mortem studies to ascertain autopsy preva-
lence of co-prevalent OIs and HAIs amongst patients with 
HIV-associated cryptococcal meningitis would be required to 
further test this hypothesis.
The prevalence of cBSI in our study population (3.5%) was 
lower than that described during the COAT (Cryptococcal Opti-
mal Anti-retroviral therapy Timing), when a cohort prevalence 
of 15% was reported11. Whilst our study was not sufficiently 
powered to detect differential bacteraemia rates across the 
anti-fungal arms, it is possible that the shortened 1-week course 
of IV amphotericin (and the oral anti-fungal arm) trialled as 
part of the ACTA trial was associated with fewer nosocomial 
intravascular line HAIs compared with the prior gold standard of 
two-weeks of IV amphotericin as used in the COAT trial. cBSI 
was similarly associated with an increased risk of death in 
the COAT trial. 50% (4/8) of the isolates in our cohort were 
multi-drug resistant, highlighting the major challenge of 
increasing anti-microbial resistance and the risk of nosocomial 
infections. 
The broad range of OIs diagnosed reflect the complexities 
in managing patients with advanced HIV and cryptococcal 
meningitis. Although co-prevalent infections were diagnosed 
throughout the 10-week study period, nearly one third of major 
co-prevalent infections were diagnosed on day one, symptoms 
of these may have contributed to hospital presentation. We there-
fore recommend that patients diagnosed with HIV-associated 
cryptococcal meningitis should be systematically screened for 
other OIs at hospital admission with targeted investigation there-
after. Additionally, the fact that around half of co-prevalent 
infections were diagnosed two weeks after antifungal initiation, 
demonstrates that patients with HIV-associated cryptococcal 
meningitis patients remain at high risk of co-prevalent infec-
tions following hospital discharge. Whilst we hypothesise 
that routine screening for key OIs and HAIs at both inpatient 
and outpatient assessments may facilitate early diagnosis and 
treatment, data on co-prevalent infections from other cryptococ-
cal cohorts to inform design of an OI screening and prevention 
intervention are limited and more research is needed.
The need for a comprehensive approach to reducing infec-
tions in advanced HIV through early ART and targeted antimi-
crobial prophylaxis has been incorporated into World Health 
Organization guidelines for the management of advanced 
HIV16. The REALITY randomised controlled trial, evalu-
ated an innovative multicomponent approach to reducing OIs 
and early mortality, demonstrating that enhanced antimicrobial 
prophylaxis (combined anti-bacterial, anti-fungal, anti-helminth, 
anti-protozoal) at ART initiation reduced early mortality in 
adults and children with a CD4 count <100 cell/mm3. A similar 
multifaceted approach to reducing mortality in HIV-associated 
cryptococcal meningitis could be adopted. Whether a protocol-
ised, goal-directed therapy approach including OI screening in 
addition to targeted anti-infectives and nutritional supplements 
would improve cryptococcal meningitis outcomes warrants 
further investigation.
This analysis has several limitations. Case notes were reviewed 
retrospectively following trial completion therefore there is 
a risk of incomplete case records and recall bias. The limited 
diagnostics available in Malawi may mean the overall 
prevalence of OIs and HAIs and in particular cBSIs could have 
been underestimated. This potential for under-ascertainment 
of exposure status may have led to an underestimation of the 
HR comparing mortality at 10-weeks between those with- and 
without major co-prevalent infections. Conversely it is possible 
that in the first few days after commencing treatment that 
cryptococcaemia-driven sepsis be classified as a sBSI leading to 
over ascertainment of sBSI.
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Conclusion
In conclusion, we have demonstrated the high prevalence 
and broad range of OIs and HAIs that occur in patients with 
HIV-associated cryptococcal meningitis. Co-prevalent infections 
were associated with a significantly increased risk of death. 
We recommend that cryptococcal meningitis patients should be 
systematically screened for OIs and HAIs. Whether a protocol-
ised approach to improve surveillance and proactive treatment 
of co-prevalent infections will further improve cryptococcal 
meningitis outcomes warrants further investigation.
Data availability
Figshare: WOR CM co-infections data file.xlsx, https://doi.
org/10.6084/m9.figshare.1329585817.
This project contains the following underlying data:
-      WOR CM co-infections data file.xlsx This data file 
describes the range, frequency, timing and outcome 
of co-infections amongst study participants with 
HIV-associated cryptococcal meningitis
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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